Skip to main content

TSRO INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation on Behalf of Tesaro, Inc. Investors

Law Offices of Howard G. Smith continues its investigation on behalf of Tesaro, Inc. (“Tesaro” or the “Company”) (NASDAQ: TSRO) investors concerning the Company and its officers’ possible violations of federal securities laws.

On January 12, 2018, Tesaro announced that it updated the U.S. labeling for Varubi (rolapitant), for the prevention of delayed nausea and vomiting associated with chemotherapy, after receiving reports of anaphylaxis, anaphylactic shock and other serious hypersensitivity reactions in the postmarketing setting, some requiring hospitalization. The Company further disclosed that it “has issued a Dear Healthcare Professional (DHCP) letter.”

On this news, shares of Tesaro fell $9.80 or 13.7%, to close at $61.86 on January 17, 2018, thereby injuring investors.

If you purchased Tesaro securities, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts:

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.